神經生物標記物市場：按類型、用途和最終用戶分類 - 2023-2030 年全球預測

全球神經生物標記市場預計將以 14.03%的年複合成長率大幅成長，到 2023 年達到 89.8769 億美元，預計到 2030 年將達到驚人的 225.6047 億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球神經生物標記市場至關重要。透過檢驗業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1. 神經生物標記的全球市場規模和預測是多少？

2.在預測期內，COVID-19 對全球神經生物標記市場的阻礙因素和影響為何？

3. 在預測期內，全球神經生物標記市場需要投資哪些產品/細分市場/應用/領域？

4.你們在全球神經生物標記市場的競爭策略是什麼？

5. 全球神經生物標記市場的技術趨勢和法律規範是什麼？

6.全球神經生物標記市場主要廠商的市佔率是多少？

7. 哪些型態和策略措施被認為適合進入全球神經生物標記市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 神經系統疾病罹患率增加
    • 對具有成本效益的非侵入性診斷系統的需求
    • 對早期診斷和預防性治療的興趣日益濃厚
  • 抑制因素
    • 政府對核准的嚴格法規
  • 機會
    • 擴大生物標記進步的研究和開發重點
    • 新型單細胞生物感測器
    • 新興國家低成本臨床試驗的成長
  • 任務
    • 倫理問題和神經系統疾病的接受問題
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 神經生物標記市場：依類型

• 基因組
• 影像
• 代謝組學
• 蛋白質體學

第7章 神經生物標記市場：依用途

• 阿茲海默氏症
• 自閉症譜系障礙
• 多發性硬化症
• 帕金森氏症

第8章 神經生物標記市場：依最終用戶分類

• 醫院實驗室
• 獨立臨床診斷中心
• 調查機構

第9章 美洲神經生物標記市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太神經生物標記市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲/中東/非洲神經生物標記市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Neurological Biomarkers Market is forecasted to grow significantly, with a projected USD 8,987.69 million in 2023 at a CAGR of 14.03% and expected to reach a staggering USD 22,560.47 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Neurological Biomarkers Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Neurological Biomarkers Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Genomic, Imaging, Metabolomic, and Proteomic. The Genomic is projected to witness significant market share during forecast period.

Based on Application, market is studied across Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson's Disease. The Autism Spectrum Disorders is projected to witness significant market share during forecast period.

Based on End-user, market is studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations. The Hospital Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Neurological Biomarkers Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neurological Biomarkers Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neurological Biomarkers Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neurological Biomarkers Market?

4. What is the competitive strategic window for opportunities in the Global Neurological Biomarkers Market?

5. What are the technology trends and regulatory frameworks in the Global Neurological Biomarkers Market?

6. What is the market share of the leading vendors in the Global Neurological Biomarkers Market?

7. What modes and strategic moves are considered suitable for entering the Global Neurological Biomarkers Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Neurological Biomarkers Market, by Type, 2022 vs 2030
• 4.3. Neurological Biomarkers Market, by Application, 2022 vs 2030
• 4.4. Neurological Biomarkers Market, by End-user, 2022 vs 2030
• 4.5. Neurological Biomarkers Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of neurological disorders
    • 5.1.1.2. Demand for cost-effective and non-invasive diagnostic system
    • 5.1.1.3. Increasing preferences on early diagnosis & preventive treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent government regulations for approvals
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing R&D focus for advancements in biomarkers
    • 5.1.3.2. Emerging single-cell biosensors
    • 5.1.3.3. Growth of low-cost clinical trials in developing countries
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical problems and acceptance issues of neurological disorders
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Neurological Biomarkers Market, by Type

• 6.1. Introduction
• 6.2. Genomic
• 6.3. Imaging
• 6.4. Metabolomic
• 6.5. Proteomic

7. Neurological Biomarkers Market, by Application

• 7.1. Introduction
• 7.2. Alzheimer's Disease
• 7.3. Autism Spectrum Disorders
• 7.4. Multiple Sclerosis
• 7.5. Parkinson's Disease

8. Neurological Biomarkers Market, by End-user

• 8.1. Introduction
• 8.2. Hospital Laboratories
• 8.3. Independent Clinical Diagnostic Centers
• 8.4. Research Organizations

9. Americas Neurological Biomarkers Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Neurological Biomarkers Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Neurological Biomarkers Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. NEUROLOGICAL BIOMARKERS MARKET RESEARCH PROCESS
• FIGURE 2. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022 VS 2030
• FIGURE 3. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 6. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
• FIGURE 7. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. NEUROLOGICAL BIOMARKERS MARKET DYNAMICS
• FIGURE 9. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 10. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 146. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 147. NEUROLOGICAL BIOMARKERS MARKET LICENSE & PRICING